Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest oncology group trial

Anti-Cancer Drugs

Volumn 11, Issue 9, 2000, Pages 695-700

  Taylor, Charles W ^a   LeBlanc, Michael ^b   Fisher, Richard I ^c   Moore Sr , Dennis F ^d   Roach, Ralph W ^e   Elias, Laurence ^f   Miller, Thomas P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Columbus CCOP ^*  (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Interleukin 4; Lymphoma; Phase II; SWOG

Indexed keywords

RECOMBINANT INTERLEUKIN 4;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LETHARGY; MALAISE; MALE; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-4; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0033664461     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200010000-00004     Document Type: Article

References (22)

1. Interleukin4: A prototypic immunoregulatory lymphokine
2. Recombinant interleukin 4 promotes the growth of human T cells
3. Evaluation of the antitumor activity of human IL4 by in vitro and in vivo assays
4. Induction of lympholine-activated killer activity by interleukin-4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro
5. Enhancement by interleukin 4 or interleukin-2 or antibody-induced proliferation of lymphocytes from interleukin-2 treated cancer patients
6. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma
7. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins
8. Biologic therapies for low-grade lymphomas
9. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms
10. Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells
11. Antiproliferative effect of interleukin-4 in B chronic lymphocytic leukemia
12. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma
13. Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice
14. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations
15. Role of lipoplysaccharide and IL-4 in control of transcription of the class n A alpha gene
16. Signal transduction mechanisms of Ia induction in B cells by interleukin 4 and immunoglobulin receptors
17. HDLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma
18. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
19. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma
20. A phase n study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer
21. Safety evaluation of recombinant human interleukin-4. II. Clinical studies
22. Acute gastric mucosal injury associated with the systemic administration of interleukin-4